Literature DB >> 29104161

Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study.

Alexis Ogdie1, Sungat K Grewal2, Megan H Noe2, Daniel B Shin2, Junko Takeshita3, Zelma C Chiesa Fuxench2, Rotonya M Carr4, Joel M Gelfand3.   

Abstract

Relatively little is known about the risk for incident liver disease in psoriasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA). We performed a cohort study among patients with PsO, PsA, or RA and matched controls in The Health Improvement Network from 1994 to 2014. Outcomes of interest were any liver disease, nonalcoholic fatty liver disease, and cirrhosis (any etiology). Among patients with PsO (N = 197,130), PsA (N = 12,308), RA (N = 54,251), and matched controls (N = 1,279,754), the adjusted hazard ratios for any liver disease were elevated among patients with PsO (without systemic therapy [ST] 1.37; with ST 1.97), PsA (without ST 1.38; with ST 1.67), and RA without an ST (1.49) but not elevated in patients with RA prescribed an ST (0.96). Incident nonalcoholic fatty liver disease was highest in patients with PsO prescribed an ST (2.23) and PsA with an ST (2.11). The risk of cirrhosis was highest among patients with PsO with an ST (2.62) and PsA without an ST (3.15). Additionally, the prevalence of liver disease and cirrhosis increased in a stepwise fashion with increasing body surface area affected by PsO (P for trend <0.001). More so than RA, PsO and PsA are associated with liver disease, particularly nonalcoholic fatty liver disease and cirrhosis, and this was true even among patients without ST exposure.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29104161      PMCID: PMC6287638          DOI: 10.1016/j.jid.2017.10.024

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  49 in total

1.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

2.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.

Authors:  James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

3.  Medical comorbidity associated with psoriasis in adults: a population-based study.

Authors:  Y-W Yang; J J Keller; H-C Lin
Journal:  Br J Dermatol       Date:  2011-09-29       Impact factor: 9.302

4.  Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.

Authors:  Luca Miele; Selenia Vallone; Consuelo Cefalo; Giuseppe La Torre; Carmine Di Stasi; Fabio M Vecchio; Magda D'Agostino; Maria L Gabrieli; Vittoria Vero; Marco Biolato; Maurizio Pompili; Giovanni Gasbarrini; Gianludovico Rapaccini; Pierluigi Amerio; Clara De Simone; Antonio Grieco
Journal:  J Hepatol       Date:  2009-06-26       Impact factor: 25.083

5.  The inflammatory response in mild and in severe psoriasis.

Authors:  P Rocha-Pereira; A Santos-Silva; I Rebelo; A Figueiredo; A Quintanilha; F Teixeira
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

6.  Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies.

Authors:  A Katrina Loomis; Shaum Kabadi; David Preiss; Craig Hyde; Vinicius Bonato; Matthew St Louis; Jigar Desai; Jason M R Gill; Paul Welsh; Dawn Waterworth; Naveed Sattar
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

7.  Diagnosis of liver cirrhosis in England, a cohort study, 1998-2009: a comparison with cancer.

Authors:  Sonia Ratib; Joe West; Colin J Crooks; Kate M Fleming
Journal:  Am J Gastroenterol       Date:  2014-01-14       Impact factor: 10.864

8.  1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998-2009: a large population study.

Authors:  Sonia Ratib; Kate M Fleming; Colin J Crooks; Guruprasad P Aithal; Joe West
Journal:  J Hepatol       Date:  2013-10-12       Impact factor: 25.083

Review 9.  Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?

Authors:  Alessandro Mantovani; Paolo Gisondi; Amedeo Lonardo; Giovanni Targher
Journal:  Int J Mol Sci       Date:  2016-02-05       Impact factor: 5.923

10.  Purposeful selection of variables in logistic regression.

Authors:  Zoran Bursac; C Heath Gauss; David Keith Williams; David W Hosmer
Journal:  Source Code Biol Med       Date:  2008-12-16
View more
  22 in total

1.  Updates in Psoriasis Management: Based on selected presentations from Maui Derm 2020, January 25-29, 2020, Maui, Hawaii.

Authors:  Jo Ann Lequang
Journal:  J Clin Aesthet Dermatol       Date:  2020-07-01

2.  Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment.

Authors:  Junko Takeshita; Whitney T Eriksen; Valerie T Raziano; Claire Bocage; Lynn Hur; Ruchi V Shah; Joel M Gelfand; Frances K Barg
Journal:  J Invest Dermatol       Date:  2019-02-06       Impact factor: 8.551

3.  SEAM-PsA: Seems Like Methotrexate Works in Psoriatic Arthritis?

Authors:  Joseph F Merola; Alexis Ogdie
Journal:  Arthritis Rheumatol       Date:  2019-07       Impact factor: 10.995

4.  Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.

Authors:  Augusta Ortolan; Mariagrazia Lorenzin; Giulia Tadiotto; Francesco Paolo Russo; Francesca Oliviero; Mara Felicetti; Renata D'Incà; Marta Favero; Stefano Piaserico; Andrea Doria; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2019-06-28       Impact factor: 2.980

5.  Hepatic steatosis as measured by the computed attenuation parameter predicts fibrosis in long-term methotrexate use.

Authors:  Marcel Tomaszewski; Monica Dahiya; Seyed Amir Mohajerani; Hanaa Punja; Hin Hin Ko; Muxin Sun; Alnoor Ramji
Journal:  Can Liver J       Date:  2021-11-11

6.  Risk of Autoimmune Diseases Following Optic Neuritis: A Nationwide Population-Based Cohort Study.

Authors:  Kevin Sheng-Kai Ma; Chee-Ming Lee; Po-Hung Chen; Yan Yang; Yi Wei Dong; Yu-Hsun Wang; James Cheng-Chung Wei; Wen Jie Zheng
Journal:  Front Med (Lausanne)       Date:  2022-06-13

Review 7.  Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.

Authors:  Jin Bu; Ruilian Ding; Liangjia Zhou; Xiangming Chen; Erxia Shen
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 8.  Psoriatic arthritis in Africa.

Authors:  Ajesh B Maharaj; Adewale Adebajo
Journal:  Clin Rheumatol       Date:  2021-06-28       Impact factor: 2.980

9.  Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.

Authors:  Ploysyne Rattanakaemakorn; Prinpat Pinyowiwat; Wimolsiri Iamsumang; Kumutnart Chanprapaph; Poonkiat Suchonwanit
Journal:  Drug Des Devel Ther       Date:  2021-05-28       Impact factor: 4.162

10.  Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment.

Authors:  Shunsuke Mori; Nobuyuki Arima; Masahiro Ito; Shigetoshi Fujiyama; Yasuhiro Kamo; Yukitaka Ueki
Journal:  PLoS One       Date:  2018-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.